Clinical study on teibivudine combined with adefuvir dipivoxii in the treatment of Hepatitis B patients with decompensated cirrhosis
10.3760/cma.j.issn.1008-6706.2012.04.003
- VernacularTitle:替比夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床研究
- Author:
Li LI
;
Weiwei DAI
;
Yanhong FENG
;
Jiabao CHANG
;
Jie QIU
;
Weifeng WU
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Liver cirrhosis;
Telbivudine;
Adefuvir dipivoxil
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(4):485-486
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of telbivudine combined with adefuvir dipivoxil in the treatment of Hepatitis B patients with decompensated cirrhosis.Methods 56 Hepatitis B patients with decompensated cirrhosis were divided into two groups:treatment group (30 cases) and control group (26 cases).During 24 weeks,the control group received adefuvir dipivoxil( 10mg daily),supportive and symptomatic treatments,while the treatment group received telbivudine therapy(600mg daily) combiled with adefuvir dipivoxil ( 10mg daily) based on the regular treatments.After 24 weeks,the effect was observed and compared between the two groups.Results After treatment,the biochemical markers,Child-Pugh score of the treatment group was (33.2 ± 13.8) μmol/L,(44.5 ± 16.4) U/L,(36.1 ±1.5) g/L,(6.1 ± 1.8) points,respectively,and was better than those of the control group[ (71.8 ±18.6) μ mol/L,(89.9 ±44.9) U/L,(29.7 ± 1.3)g/L,(8.1 ±2.2) points] (t=15.32,15.20,23.37,6.09,all P＜0.05) ;HBV-DNA negative rate,HBeAg seroconversion rates of the treatment group was 93.3％ (28/30),43.3％(13/30),and was higher than that of the control group[76.9％ (20/26),7.6％ (2/26) ] (x2 =4.87,9.08,all P＜0.05).Conclusion Telbivudine combined with adefuvir dipivoxil was effective and safe for the treatment of Hepatitis B patients with decompensated cirrhosis.
